Press the dose button on the pen to inject the medication
Because retatrutide is not yet licensed in the UK, individuals who are participating in clinical trials or who have accessed the drug through other means should maintain open communication with a qualified healthcare professional
Retatrutide is the injectable triple agonist that hits GLP-1, GIP, and glucagon receptors at once, and it reached up to 24.2 percent average body weight loss in its Phase 2 obesity trial
Possible signs of an overdose can include severe nausea, persistent vomiting, dizziness, or symptoms of low blood sugar, like shakiness, sweating, confusion, or a rapid heartbeat
The clear influence of therapeutic GLP-1 analogs on the physiology of the digestive system as well as the stability and diversity of the gut microbiota deserves special attention because disorders of the gut-brain axis homeostasis also appear to be an important, although so far somewhat understudied factor, which may lead to the development of depression
Dong et al., 2022